Fycompa – Important Safety Information

January 6, 2022

FYCOMPA® (perampanel) is indicated in patients with epilepsy aged 4 years and older for partial‑onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy for patients aged 12 years and older for primary generalized tonic‑clonic (PGTC) seizures.

See full prescribing information for complete boxed warning HERE:

WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS

• Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation
and threats have been reported in patients taking FYCOMPA (5.1)
• Monitor patients for these reactions as well as for changes in mood, behavior, or personality that are not typical for the patient, particularly
during the titration period and at higher doses (5.1)
• FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening.

Related Posts

Medication Recall Alert Sabril® (Vigabatrin)

Medication Recall Alert Sabril® (Vigabatrin)

Our friends at the Epielpsy Foundation have shared the Following Medication Recall The company that makes Sabril® (vigabatrin) for oral solution, a prescription medication to manage seizures in children and adults, has announced a recall of this medication because of...

MEDICATION ALERT – FELBAMATE (Generic)

MEDICATION ALERT – FELBAMATE (Generic)

We understand that some families in our community may be having challenges getting prescriptions filled for generic Felbamate oral suspension and tablets. If you need assistance with obtaining your medication, contact our 24/7 Helpline at 1-800-332-1000 for connection...

Medicaid Eligibility Renewals are Coming!

Medicaid Eligibility Renewals are Coming!

Medicaid Eligibility Renewals are Coming! Medicaid eligibility renewals were paused during the COVID-19 pandemic but are re-starting soon. This means that almost everyone on Medicaid in the US will need to renew their eligibility at some point between February 2023...